http://blogs.mercola.com/sites/vitalvotes/archive/2009/07/17/Squalene-The-Swine-Flu-Vaccines-Dirty-Little-Secret-Exposed.aspx
And as if Vaccines Weren’t Dangerous Enough on Their Own …
… imagine them turbocharged.
The main ingredient in a vaccine is either killed viruses or live ones that have been attenuated (weakened and made less harmful).
Flu vaccines can also contain a number of chemical toxins, including ethylene glycol (antifreeze), formaldehyde, phenol (carbolic acid) and even antibiotics like Neomycin and streptomycin.
In addition to the viruses and other additives, many vaccines also contain immune adjuvants like aluminum and squalene.
The purpose of an immune adjuvant added to a vaccine is to enhance (turbo charge) your immune response to the vaccination. Adjuvants cause your immune system to overreact to the introduction of the organism you’re being vaccinated against.
Adjuvants are supposed to get the job done faster (but certainly not more safely), which reduces the amount of vaccine required per dose, and the number of doses given per individual.
Less vaccine required per person means more individual doses available for mass vaccination campaigns. Coincidentally, this is exactly the goal of government and the pharmaceutical companies who stand to make millions from their vaccines.
Will There Be Immune Adjuvants in Swine Flu Vaccines?
The U.S. government has contracts with several drug companies to develop and produce swine flu vaccines. At least two of those companies, Novartis and GlaxoSmithKline, are using an adjuvant in their H1N1 vaccines.
The adjuvant? Squalene.
According to Meryl Nass, M.D., an authority on the anthrax vaccine,
“A novel feature of the two H1N1 vaccines being developed by companies Novartis and GlaxoSmithKline is the addition of squalene-containing adjuvants to boost immunogenicity and dramatically reduce the amount of viral antigen needed. This translates to much faster production of desired vaccine quantities.”[v]
Novartis’s proprietary squalene adjuvant for their H1N1 vaccine is MF59. Glaxo’s is ASO3. MF59 has yet to be approved by the FDA for use in any U.S. vaccine, despite its history of use in other countries.
Per Dr. Nass, there are only three vaccines in existence using an approved squalene adjuvant. None of the three are approved for use in the U.S.
